Search

Displaying results 2011 - 2020 of 4590 in total
  1. Drug

    Tasimelteon

    go.drugbank.com/drugs/DB09071
    ApprovedInvestigational

    By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism … Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.

  2. Drug

    Temafloxacin

    go.drugbank.com/drugs/DB01405
    ApprovedWithdrawn

    It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three

  3. Drug

    Glutathione disulfide

    go.drugbank.com/drugs/DB03310
    Approved

    A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.

  4. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] Rusfertide is administered by subcutaneous injection and titrated to maintain hematocrit below 45%.

  5. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in … 1955 by G.D Searle & Company.

  6. Drug

    Solenopsis richteri

    go.drugbank.com/drugs/DB11026
    Approved

    When stung, the bites are characterized by sterile pustules that are surrounded by reddened swelling along with redness extending beyond.

  7. Drug

    Losartan

    go.drugbank.com/drugs/DB00678
    ApprovedInvestigational

    [L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.

  8. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    [A181244,L7495] Initially approved in 2014, it is marketed by Celgene.

  9. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased

  10. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer